Literature DB >> 19650787

Silent corticotroph adenomas have unique recurrence characteristics compared with other nonfunctioning pituitary adenomas.

Hwa Young Cho1, Sun Wook Cho, Sang Wan Kim, Chan Soo Shin, Kyong Soo Park, Seong Yeon Kim.   

Abstract

OBJECTIVE: The prevalence of silent corticotroph adenomas (SCAs) is not rare among nonfunctioning pituitary adenomas (NFPAs); however, it is unknown whether the clinical significance of SCAs differs from that of NFPAs without ACTH immunoreactivity (non-SCAs). Our goal was to compare the clinical characteristics and natural history between patients with SCAs and non-SCAs. DESIGN/PATIENTS: We reviewed the medical records of all patients who underwent transsphenoidal surgery for NFPAs from January 1990 to October 2007 at the Seoul National University Hospital. MEASUREMENTS: We analysed whether clinical manifestations at diagnosis, postoperative recurrence rate and recurrence characteristics differed between SCA and non-SCA patients.
RESULTS: In total, 28 patients with SCAs and 134 patients with non-SCAs were analysed. The mean age at the time of diagnosis was 44 years (range, 13-67 years) in the SCA group and 50 years (18-79 years) in the non-SCA group (P = 0.026), with respective follow-up periods of 5.2 (range, 1.0-16.0 years) and 4.2 years (0.5-16.1 years) (P = 0.255). Overall recurrence rates of SCAs and non-SCAs were 25.0% and 26.9% respectively (P = 0.839). More than two recurrences (P = 0.001) and recurrence after more than 5 years (P = 0.040) were associated with SCAs. Multiple recurrences of SCAs were confined to younger patients.
CONCLUSION: The overall recurrence rate was similar between SCAs and non-SCAs. However, young patients with SCAs had a higher frequency of multiple and late recurrences, which showed more aggressive tumour behaviour. Therefore, we suggest that patients with SCAs, especially patients diagnosed at a young age, require careful long-term monitoring.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19650787     DOI: 10.1111/j.1365-2265.2009.03673.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  23 in total

Review 1.  Subclinical hyperfunctioning pituitary adenomas: the silent tumors.

Authors:  Odelia Cooper; Shlomo Melmed
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2012-05-22       Impact factor: 4.690

2.  Prognostic significance of corticotroph staining in radiosurgery for non-functioning pituitary adenomas: a multicenter study.

Authors:  Or Cohen-Inbar; Zhiyuan Xu; Cheng-Chia Lee; Chin-Chun Wu; Tomáš Chytka; Danilo Silva; Mayur Sharma; Hesham Radwan; Inga S Grills; Brandon Nguyen; Zaid Siddiqui; David Mathieu; Christian Iorio-Morin; Amparo Wolf; Christopher P Cifarelli; Daniel T Cifarelli; L Dade Lunsford; Douglas Kondziolka; Jason P Sheehan
Journal:  J Neurooncol       Date:  2017-09-14       Impact factor: 4.130

Review 3.  Predictors of silent corticotroph adenoma recurrence; a large retrospective single center study and systematic literature review.

Authors:  Fabienne Langlois; Dawn Shao Ting Lim; Chris G Yedinak; Isabelle Cetas; Shirley McCartney; Justin Cetas; Aclan Dogan; Maria Fleseriu
Journal:  Pituitary       Date:  2018-02       Impact factor: 4.107

Review 4.  Silent (clinically nonfunctioning) pituitary adenomas.

Authors:  Sarah E Mayson; Peter J Snyder
Journal:  J Neurooncol       Date:  2014-03-28       Impact factor: 4.130

Review 5.  Silent corticotroph adenomas.

Authors:  Odelia Cooper
Journal:  Pituitary       Date:  2015-04       Impact factor: 4.107

6.  Silent corticogonadotroph adenomas: clinical and cellular characteristics and long-term outcomes.

Authors:  Odelia Cooper; Anat Ben-Shlomo; Vivien Bonert; Serguei Bannykh; James Mirocha; Shlomo Melmed
Journal:  Horm Cancer       Date:  2010-04       Impact factor: 3.869

7.  ASSESSMENT AND COMPARISON OF HORMONAL IMMUNOEXPRESSION AND THE CLINICAL PICTURE IN PATIENTS WITH PITUITARY ADENOMAS.

Authors:  B Kwinta; A Myszka; R M Krzyżewski; K M Kliś; M R Dragan; D Adamek
Journal:  Acta Endocrinol (Buchar)       Date:  2020 Apr-Jun       Impact factor: 0.877

8.  The role of mediators of cell invasiveness, motility, and migration in the pathogenesis of silent corticotroph adenomas.

Authors:  Ozgur Mete; Caroline Hayhurst; Hussein Alahmadi; Eric Monsalves; Hasan Gucer; Fred Gentili; Shereen Ezzat; Sylvia L Asa; Gelareh Zadeh
Journal:  Endocr Pathol       Date:  2013-12       Impact factor: 3.943

9.  Silent subtype 3 pituitary adenomas are not always silent and represent poorly differentiated monomorphous plurihormonal Pit-1 lineage adenomas.

Authors:  Ozgur Mete; Karen Gomez-Hernandez; Walter Kucharczyk; Rowena Ridout; Gelareh Zadeh; Fred Gentili; Shereen Ezzat; Sylvia L Asa
Journal:  Mod Pathol       Date:  2016-01-08       Impact factor: 7.842

Review 10.  Aggressive Cushing's Disease: Molecular Pathology and Its Therapeutic Approach.

Authors:  Masaaki Yamamoto; Takahiro Nakao; Wataru Ogawa; Hidenori Fukuoka
Journal:  Front Endocrinol (Lausanne)       Date:  2021-06-16       Impact factor: 5.555

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.